Celldex (CLDX) Therapeutics announced positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis-thymic stromal lymphopoietin and mast cell depletion via stem cell factor starvation. The data demonstrate that CDX-622 neutralizes both SCF and TSLP, reducing tissue mast cells and inhibiting Type 2 inflammatory responses, supporting its potential to improve clinical activity over single target inhibition in inflammatory diseases and fibrotic disorders. The data were presented by Diego Alvarado, PhD, Vice President of Research at Celldex Therapeutics, in a poster presentation as part of the American Academy of Allergy, Asthma & Immunology Annual Meeting 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex’s Promising Clinical Developments and Strategic Advancements Lead to Buy Rating
- Celldex announces data from Phase 2 barzolvolimab studies
- Celldex: Strong Financial Position and Promising Pipeline Drive Buy Rating
- Celldex Therapeutics Advances Pipeline Amid Financial Challenges
- Celldex Buy Rating: Promising Clinical Advancements and Strong Financial Position Drive Positive Outlook
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue